<DOC>
	<DOCNO>NCT02537054</DOCNO>
	<brief_summary>The purpose study determine whether Aflibercept ( Eylea ) effective treatment choroidal neovascularization fibrovascular proliferation patient pseudoxanthoma elasticum ( PXE ) term preservation improvement visual acuity .</brief_summary>
	<brief_title>Intravitreal Aflibercept Therapy Patients With Pseudoxanthoma Elasticum ( PXE )</brief_title>
	<detailed_description />
	<mesh_term>Choroidal Neovascularization</mesh_term>
	<mesh_term>Pseudoxanthoma Elasticum</mesh_term>
	<criteria>Diagnosis PXE moleculargenetic diagnosis and/or skin biopsy Diagnosed CNV FVP Age 1865 year Voluntary participation study proven write informed consent Ability follow study instruction likely attend complete require visit Best correct visual acuity 20/400 20/20 treat eye Male female patient childbearing potential must use approved contraceptive method ( Pearl Index &lt; 1 ) trial Premenopausal female patient childbearing potential : negative pregnancy test must obtain Subject unable understand nature , scope , significance consequence clinical trial Patients know allergy hypersensitivity Eylea preparation similar chemical structure Treatment another clinical trial therapeutic intervention use investigational medicinal product ( IMP ) trial within 30 day enrolment Known persistent abuse medication , drug alcohol Women pregnant breast feed Lack eligibility discretion investigator Ocular operation within month prior enrolment Noncontrolled glaucoma Active intraocular inflammation inflammation ocular adnexa Other disease result distinct visual constraint Distinct opacification optical medium Distinct subretinal fibrosis /or atrophy prevents relevant treatment effect Aflibercept discretion investigator Serious cardiovascular problem stroke within 6 month enrolment Simultaneous use Vascular Endothelial Growth Factor ( VEGF ) inhibit medication ( systemic ocular ) within month prior enrolment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Choroidal neovascularization</keyword>
	<keyword>Angioid streak</keyword>
	<keyword>Pseudoxanthoma Elasticum</keyword>
	<keyword>vascular endothelial growth factor</keyword>
	<keyword>aflibercept</keyword>
</DOC>